The year 2020 has been an extraordinary year in many ways but especially for patients with lupus nephritis (LN), as 2020 saw two novel agents (belimumab and voclosporin) finding FDA-approval for the treatment of LN. These agents will both enrich the therapeutic armamentarium, allowing physicians to better treat their LN patients, as well as broaden treatment strategies that can be employed.
In this pro-con debate, I will highlight the trial data that have led to the FDA approval of belimumab and voclosporin for the treatment of LN. I will also address the unmet needs these new compounds can address in the treatment of LN. Lastly, the potential treatment strategies emerging from the approval of these new agents will be addressed.
Describe the evidence for the latest FDA-approved drugs for LN: Belimumab and voclosporin
Describe the current challenges physicians face when treating patients with LN
Describe possible new treatment strategies for patients with LN
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.